BioSpace News Archive

Outlook Therapeutics, Inc. (Nasdaq: OTLK) is a late clinical-stage biopharmaceutical company developing the first FDA-approved ophthalmic formulation of bevacizumab-vikg (LYTENAVA™) for use in retinal indications (known as ONS-5010). Outlook Therapeutics is advancing on multiple fronts, including: progress on its Phase 3 clinical program, manufacturing and regulatory activities, and global strategic partnering negotiations, all lead

- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO for the treatment of solid tumors and tumor metastases, today announced that a virtual poster presentation has been accepted for the AACR Conference on Tumor Immunol

Results from signal-finding, pilot Phase 2 open-label ARCADE study and ENDYMION long-term extension study in CDKL5 deficiency disorder (CDD) and Dup15q syndrome (Dup15q) show seizure frequency reduction over time In CDD patients, median motor seizure frequency reduction was 24% in the ARCADE study, increasing to a 50% reduction in ENDYMION long-term extension study Clinical Global Impression of Change (CGI-C) and Caregiver Global Impression of Change (Care GI-C) suggest improvements beyond

The Lung Health Foundation and Lung Cancer Canada have joined forces to highlight the hurtful and deadly effects of lung cancer stigma through Stop Asking the Wrong Question, a powerful new awareness campaign launched Canada-wide

Avenu’s Percutaneous Fistula Creation Technology Will Strengthen the Medtronic Peripheral Vascular Access Portfolio and Reinforce Medtronic’s Commitment to Improving Outcomes for Patients with End-Stage Renal Disease DUBLIN , Sept. 30, 2020 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the planned acquisition of Aven

Elevation Oncology, a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, and US Oncology Research, one of the largest community-based oncology site management organizations in the U.S., announced today a collaboration to utilize the US Oncology Research Selected Trials for Accelerated Rollout (STAR) program for patient enrollment in the registration-enabling Phase 2 CRESTONE study

Shatterproof’s National Movement to End Stigma and online Addiction Treatment Needs Assessment Tool offer resources dedicated to better addressing the needs of those struggling with addiction

Susan G. Komen®, the world’s leading breast cancer organization, recognized two widely respected and innovative breast cancer researchers this week, announcing that Donald McDonnell, Ph.D., and Laura Esserman, M.D., have been selected as this year’s recipients of the Brinker Awards – Komen’s highest scientific honor. Establish

Citi today announced a collaboration with Truvalue Labs, the pioneer in AI-driven environmental, social, and governance (ESG) data, to accelerate its ESG research initiatives and to analyze company ESG behavior at scale.

CytRx Corporation (OTCQB:CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today congratulated Orphazyme A/S (ORPHA.CO) (NASDAQ:ORPH) (“Orphazyme”) on the September 29, 2020 pricing of its global offering, consisting of an initial public offering of American Depositary Shares in the U.S. and a concurrent priv